Skip to main content

Advertisement

Table 3 Patients with CNS demyelinating diseases and controls according to their serum AQP4-IgG and MOG-IgG mediated complement activation measured by the formation of the terminal complement complex (TCC)

From: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

  TCC AQP4-MOG- TCC AQP4+MOG- TCC AQP4-MOG+ p-value
Number 69 27 17  
Females1 44 (64%) 25 (93%) *§ 11 (65%) 0.017
Disease2     
NMO (n = 23) 6 (26%) 15 (65%) 2 (9%) < 0.001
HR-NMO (n = 33) 17 (52%) 11 (33%) 5 (15%)  
ADEM (n = 19) 11 (58%) 0 (0%) 8 (42%)  
CIS (n = 14) 12 (86%) 1 (7%) 1 (7%)  
MS (n = 10) 10 (100%) 0 (0%) 0 (0%)  
CTRL (n = 14) 13 (93%) 0 (0%) 1 (7%)  
Age (y)3 38 (8-74) 48 (19-80) * 13 (2-56) *# < 0.001
AQP4 IgG1 16 (23%) 27 (100%) *§ 0 (0%) * < 0.001
Titer (1:)3 0 1,280 *§ 0 < 0.001
  (0-1,280) (160-20,480) (0)  
MOG IgG1 7 (10%) 0 (0%) 17 (100%) *# < 0.001
Titer (1:)3 0 0 2,560 *# < 0.001
  (0-2,560) (0-20) (640-20,480)  
  1. Patients with NMO (n = 23), HR-NMO (n = 33), ADEM (n = 19), CIS (n = 14), MS (n = 10) and CTRL (n = 14) were grouped according to TCC formation: TCC AQP4 and MOG negative patients (AQP4-MOG-), TCC AQP4 positive and MOG negative (AQP4+MOG-) and TCC AQP4 negative and MOG positive (AQP4-MOG+). In detail, the antibody serostatus (AQP4-IgG/MOG-IgG) and titer levels of the patients investigated for TCC formation are listed in the additional file 3. P-value: groups were compared using1 Fisher's exact test,2 Chi-square test and3 Mann-Whitney U test (data are shown as median with range); * statistically different from TCC AQP4-MOG-; # statistically different from TCC AQP4+MOG-; § statistically different from TCC AQP4-MOG+ (p-values were corrected for multiple comparisons). Abbreviations: TCC = terminal complement complex, y = years.